Larimar Therapeutics, Inc. Income Statement

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.10M-0.87M-0.81M-0.53M-0.17M-1.90M-1.77M
Gross Profit -0.10M-0.87M-0.81M-0.53M-0.17M-1.90M-1.77M
Operating items
Research & Development 11.54M9.56M27.39M54.62M39.94M40.84M47.93M23.89M
Selling, General & Administrative 2.25M4.22M8.14M19.20M18.29M12.16M13.19M16.21M
Restructuring Costs 5.55M
Operating Expenses 13.79M13.78M35.53M73.81M58.23M53.00M61.12M45.65M
Operating Income -13.79M-13.78M-35.53M-73.81M-58.23M-53.00M-61.12M-45.65M
EBIT -13.79M-13.78M-35.53M-73.81M-58.23M-53.00M-61.12M-45.65M
Non-operating items
Non Operating Investment Income -0.04M
Interest & Investment Income 0.03M0.44M0.89M1.00M1.89M1.99M
Other Non Operating Income 0.01M-0.25M-0.10M-0.10M-0.02M0.14M-0.24M0.03M
Non Operating Income -0.09M-0.25M-0.95M-0.47M0.35M0.97M-0.25M0.25M
Net income details
EBT -13.89M-13.78M-36.37M-74.18M-57.86M-52.17M-61.13M-45.43M
Profit After Tax -13.88M-14.03M-36.48M-74.29M-57.88M-52.03M-61.37M-45.41M
Income from Continuing Operations -13.89M-13.78M-36.37M-74.18M-57.86M-52.17M-61.13M-45.43M
Consolidated Net Income -13.89M-13.78M-36.37M-74.18M-57.86M-52.17M-61.13M-45.43M
Income towards Parent Company -13.89M-13.78M-36.37M-74.18M-57.86M-52.17M-61.13M-45.43M
Preferred Dividend Payments 0.07M0.21M0.09M
Net Income towards Common Stockholders -13.95M-14.24M-36.57M-74.29M-57.88M-52.17M-61.13M-45.43M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 1.89M2.27M2.28M2.29M3.07M3.11M15.36M17.71M43.27M43.91M63.81M
EBITDA -13.88M-14.03M-36.51M-74.46M-57.75M-52.01M-61.34M-45.34M